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The prognosis of patients with scirrhous gastric cancer is extremely poor.  The manage-
ment protocol for this type of cancer has not well been documented.  In this paper, re-
cent therapeutic outcomes of this type of gastric cancer are reviewed, and we introduce a 
new treatment protocol for scirrhous gastric cancer.
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Special Contribution
Clinicopathological characteristics of 
scirrhous gastric cancer
 
Scirrhous gastric cancer, designated as linitis plas-
tica or Borrmann type 4 gastric cancer, is unique 
among gastric carcinomas.  It is characterized by 
poorly differentiated carcinoma cells or signet-
ring cells which diffusely infiltrate the gastric 
wall with provoking reactive ﬁbrosis.  Scirrhous 
gastric cancerous cells are located predominantly 
in the submucosa, making it difﬁcult to identify 
scirrhous gastric cancer using endoscopy.  Al-
though accuracy in the diagnosis of other gastric 
carcinomas has undoubtedly improved with the 
advent of endoscopy (Qizilbash et al., 1980), the 
sensitivity of detection of scirrhous gastric cancer 
by endoscopy was reported to be only 33 to 73% 
(Evans et al., 1985; Levine et al., 1990).  More-
over, Park et al. (2004) indicated that detection of 
scirrhous gastric cancer using upper gastrointesti-
nal series or endoscopic examinations at an early 
stage was quite difficult.  Contrary to normal 
cases of gastric cancers, scirrhous gastric cancer 
tends to spread over the peritoneum with a rapid 
growth and early metastasis (Aranha et al., 1989; 
Kanter et al., 1986).  Thus, prognosis is poor in 
patients with this disease, and the 5-year survival 
rate is low.
 
 
Prognosis of patients with scirrhous gas-
tric cancer
 
Despite curative gastrectomy, the 5-year survival 
rate following gastric resection for patients with 
scirrhous cancer (13%) is signiﬁcantly lower than 
that of patients with other types of carcinoma 
(67%) (Otsuji et al., 2004).  High incidences of se-
rosal invasion and peritoneal metastasis have been 
reported in scirrhous gastric cancer, and many 
reports indicated that palliative resection of the 
stomach resulted in poor outcomes for affected 
patients (Takahashi et al., 2000; Yoshikawa et al., 
2001).  Even when curative gastrectomy is per-
formed, survival of patients remains low.  Thus, 
Aranha et al. (1989) suggested that scirrhous gas-
tric cancer was not a surgical disease. 
 In our previous study, between 1991 and 
2001, scirrhous gastric cancer was detected in 58 
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Fig. 1.  Our therapeutic results for patients with scirrhous gastric cancer who underwent gastrectomy be-
tween 1991 and 2001. Survival curves of 39 patients. 
 Line a: 19 patients with no peritoneal metastasis (P) and no peritoneal washing cytology [P(–)/CY(–)]. 
 Line b: 7 patients with P(–)/CY(+).
 Line c: 13 patients with P(+)/CY(+). 
(7.5%) of 774 patients with gastric cancers treated 
at the Tottori University Hospital.  Gastrectomy 
was performed in 39 (67.2%) patients; and in the 
other 19 patients, gastrectomy was not performed 
(nine of them already had pleural effusion or 
ascites at diagnosis of scirrhous gastric cancer, 
and the other 10 were operated on, but gastrec-
tomy was halted because metastasis was widely 
detected in the peritoneal cavity).  Peritoneal in-
traoperative cytology of washings (CY) from the 
Douglas cavity was performed for the 39 patients 
immediately after laparotomy, according to a 
previously demonstrated method (Ikeguchi et al., 
1994).  Of the 39 scirrhous gastric cancer patients 
who underwent gastrectomy, the 5-year survival 
rate of 19 patients with no peritoneal metastasis (P) 
and no peritoneal washing cytology [P(–)/CY(–)] 
was 11.6%, and 13 patients with P(+)/CY(+) or 7 
patients with P(–)/CY(+) died within 3 years of 
operation.  The survival curve of patients with 
P(–)/CY(–) was better than that of patients with 
P(–)/CY(+) (P = 0.007), and survival curve of 7 
patients with P(–)/CY(+) was not different from 
that of 13 patients with P(+)/CY(+) (Fig. 1, P = 
0.262).  Moreover, the 50% survival periods of 
20 patients with P(–)/CY(+) or P(+)/CY(+) who 
underwent gastrectomy (5 months) was almost 
the same as that of 10 patients who were oper-
ated with only laparotomy (because of extended 
peritoneal metastasis, 6 months, P = 0.725).  Our 
data strongly suggested that in scirrhous gastric 
cancer, gastrectomy should be performed for pa-
tients with P(–)/CY(–).  Similar results have been 
reported by Kikuchi et al. (2000). 
 
 
Therapeutic procedures and outcomes  
of scirrhous gastric cancer
 
To prolong the survival periods of patients with 
scirrhous gastric cancer, some surgeons have per-
formed more radical operations such as en bloc 
total gastrectomy including the pancreatic body 
and tail, the spleen, the gallbladder, the transverse 
colon and the left adrenal gland (Furukawa et 
al., 1997).  However, such radical surgeries may 
result in increased risks of operative mortality. 
Although other treatments have been attempted 
such as chemotherapy (Kobayashi et al., 2002), 
radiotherapy (Willett, 2002), hormonal therapy 
(Furukawa et al., 1994) or immunotherapy (Kim 
et al., 2001), their antitumor effects have been 
insufﬁcient to improve prognosis of patients with 
scirrhous gastric carcinoma. 
 Common features of scirrhous gastric cancer 
include remarkable fibrosis, rapid invasive pro-
gression and high frequency of metastasis to the 
peritoneum.  Using a nude mouse model, Hippo 
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Fig. 2.  Our new treatment design for scirrhous gastric cancer using laparoscopic cisplatin-based 
intraperitoneal chemotherapy.  
et al. (2001) globally analyzed differential gene 
expression in scirrhous gastric cancer cells, and 
they indicated that scirrhous gastric cancer cells 
showed a particularly high potential for metasta-
sis to the peritoneal cavity.  Thus, development of 
new therapeutic approaches to prevent peritoneal 
metastasis is an important issue. 
 
 
Intraperitoneal chemotherapy  
for scirrhous gastric cancer
 
Various investigators have attempted to develop 
therapies against peritoneal metastasis in scir-
rhous gastric carcinoma.  Hagiwara et al. (1992) 
reported prognostic effectiveness of intraperito-
neal administration of mitomycin-C at the time of 
operation in patients with advanced gastric can-
cer.  In addition, we have previously reported that 
intraperitoneal chemotherapy showed a survival 
beneﬁt for patients with advanced gastric cancer 
who had free cancerous cells in their peritoneal 
cavities (Hamazoe et al., 1994).  Thus, we sug-
gested that intraperitoneal chemotherapy might 
have prognostic benefits for patients with scir-
rhous gastric cancer, by preventing peritoneal me-
tastasis.  Moreover, Tsujitani et al. (1993) reported 
that foci of peritoneal seeding were more sensitive 
to cisplatin than to mitomycin C or to adriamy-
cin.  Thus, we used cisplatin in our new treatment 
protocol (using intraperitoneal chemotherapy) for 
scirrhous gastric cancer patients. 
 
 
Our new treatment design  
for scirrhous gastric cancer
 
Shiraishi et al. (1999) reported that laparoscopy 
was useful for evaluating peritoneal metastatic 
statuses.  Therefore, to avoid unnecessary lapa-
rotomy, we used laparoscopy for the diagnosis of 
macroscopic peritoneal metastases or to perform 
peritoneal washing cytology for patients with 
scirrhous gastric cancer.  Moreover, we used in-
traperitoneal chemotherapy with cisplatin during 
laparoscopy for these patients regardless of peri-
toneal status.  We started this new treatment for 
patients with scirrhous gastric cancer from 2002 
(Fig. 2).  Patients with scirrhous gastric cancer 
without pleural effusion, ascites, liver metastasis 
or extended lymph nodes metastasis by computed 
tomography, were treated using laparoscopic di-
agnosis of peritoneal metastasis and peritoneal 
washing cytology under general anesthesia.  Dur-
ing this procedure, intraperitoneal chemotherapy 
with cisplatin (50 mg/m2) in 1000-mL saline was 
performed through a drain tube located in the left 
sub-diaphragm; and following 1 h after clamping 
Day 2
Cisplatin:  50 mg/m2 
with 1000 mL saline
Day 4
Cisplatin:  50 mg/m2 
with 1000 mL saline
Day 0
Cisplatin:  50 mg/m2 
with 1000 mL saline
Day 5
Real-time RT-PCR using CEA mRNA probe 
for peritoneal washings after chemotherapy
Laparoscopic observation under 
general anesthesia
1 Washing cytology
2 Real-time RT-PCR using CEA mRNA probe 
for peritoneal washings before chemotherapy
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of the drain tube, saline with cisplatin was dis-
charged from the drain tube located at the pouch 
of Douglas (Fig. 3).  This type of intraperitoneal 
chemotherapy was performed thrice on every oth-
er day (initial chemotherapy was performed dur-
ing laparoscopic diagnosis under general anesthe-
sia, but following intraperitoneal chemotherapies 
were performed without anesthesia).  Following 
the end of intraperitoneal chemotherapy, patients 
were treated with systemic chemotherapy using 
5-ﬂuorouracil (500 mg/m2) and cisplatin (10 mg/
m2), intravenously for 4 days/week.  Systemic che-
motherapy was maintained for 4 weeks.  Patients 
who were diagnosed as P(–) at initial laparoscopy 
underwent gastrectomy with lymphadenectomy 
after systemic chemotherapy.  Patients who were 
diagnosed as P(+) received intraperitoneal chemo-
therapy using laparoscopy under general anesthe-
sia for more than twice (Ikeguchi et al., 2005). 
 
 
Detection of cancerous cells  
in peritoneal washing samples  
using real-time RT-PCR
 
In order to investigate therapeutic effects of intra-
peritoneal chemotherapy for patients with gastric 
cancer, we analyzed numbers of cancerous cells in 
peritoneal washing samples obtained just prior to 
and after intraperitoneal chemotherapy using car-
cinoembryonic antigen (CEA) mRNA based real-
time reverse transcription (RT)-PCR.  One hun-
dred and ﬁfty milliliters of saline were introduced 
into the Douglas cavity of each individual at the 
beginning of laparoscopic operations, and aspi-
rated after gentle stirring.  Fifty-milliliter samples 
of each peritoneal washing were prepared for cyto-
logical diagnosis of free cancerous cells, and other 
50-mL samples were used for RNA extraction.  At 
post-operative day 5 (after the end of intraperitone-
al chemotherapy), peritoneal cavities of scirrhous 
patients were washed with 150-mL saline from the 
tube located on the left sub-diaphragm.  Fifty mil-
liliters of peritoneal washing were then collected 
from the tube located at the pouch of Douglas for 
RNA extraction.  Cytological examination was 
not performed at this time, because it was usually 
difﬁcult to gather sufﬁcient volume of samples for 
cytological examination. 
 Fifty milliliters of peritoneal wash samples 
were centrifuged for 10 min at 400 × g, and total 
RNA was extracted from the resulting pellets 
using an RNeasy Mini Kit (Qiagen, Hilden, Ger-
many) according to the manufacturer’s protocol. 
cDNA was synthesized from 1 µg total RNA us-
ing Ready-to-Go You-Prime First-Strand Beads 
(Amersham Pharmacia Biotech, Piscataway, NJ). 
Specific primers and a TaqMan probe for CEA 
were synthesized (Ikeguchi et al., 2003).  PCR 
was carried out with incubation at 50°C for 2 min, 
denaturing at 95˚C for 10 min, 45 cycles at 95˚C 
for 15 s and 61˚C for 1 min (Bustin et al., 1991).  
 Different concentrations of KATO-III cells 
(10–106) were added to 1.5-mL peripheral blood 
samples from 1 healthy volunteer (6 × 106 periph-
eral blood granulocytes).  CEA mRNA expression 
levels from different concentrations of KATO-
III cells were analyzed by real-time RT-PCR. 
All PCR experiments were done in triplicates. 
Numbers of cancerous cells were derived from 
the CEA calibration curve (Yajima et al., 1998) 
derived from plots representing the log of KATO-
III cells in 6 × 106 granulocytes on the x-axis and 
cycle numbers on the y-axis.  Therefore, formula 
for CEA expression was y = 40 – 3x (r2 = 0.994) 
Fig. 3.  Locations of tubes during intraperitoneal 
chemotherapy.  A: drain tube located in the left sub- 
diaphragm.  B: drain tube located at the pouch of Douglas.
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(Fig. 4).  For each peritoneal washing sample, 
relative numbers of cancerous cells (amounts of 
CEA mRNA) were determined from the standard 
curve (Nakanishi et al., 2000).  
 
 
Therapeutic beneﬁts of laparoscopic  
intraperitoneal chemotherapy for  
patients with scirrhous gastric cancer
 
Between 2002 and 2005, 13 patients were diag-
nosed as scirrhous gastric cancer and diagnosed 
as no pleural effusion, no ascites, no liver metas-
tasis or no extended lymph node metastasis by 
computed tomography.  They were performed 
laparoscopic diagnosis for peritoneal metastasis 
followed by intraperitoneal chemotherapy.  De-
tails of these patients are summarized in Table 
1.  Four patients were diagnosed as P(+)/CY(+), 
3 were as P(–)/CY(+) and 6 were as P(–)/CY(–). 
While, cancerous cells were detected in peritoneal 
washings of all 13 patients using CEA-based real-
time RT-PCR.  More than 90% of cancerous cells 
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Fig. 4.  The standard curve based on the different con-
centration of KATO-III cells in 6 × 106 granulocytes. 
The log of KATO-III cells in 6 × 106 granulocytes was 
set on the x-axis. The threshold line was set at an Rn 
of 0.1.  The cycle numbers at which each amplifica-
tion curve of the different concentration of KATO-III 
crossed the threshold (0.1) was set on the y-axis.  For 
each sample, the number of cancer cells was estimated 
from this standard curve and it was described as the 
number of cancer cells/6 × 106 granulocytes. 
were removed from the peritoneal cavity follow-
ing cisplatin intraperitoneal treatment in 8 patients 
(Table 1).  Moreover, CEA-positive cells could not 
Table 1. 　Characteristics of the 13 scirrhous gastric cancer patients treated with laparoscopic 
intraperitoneal chemotherapy 
Patient Age      Sex P/CY     Number of cancerous cells/ Cancerous cells† Gastrectomy  Prognosis§ 
 num-    (year)            6 × 106 granulocytes reduced after  after  after intra-
  ber            Before               After  chemotherapy  chemotherapy peritoneal
    chemotherapy  chemotherapy (%)  chemotherapy
    1 55 F +/+ 263,027 23,988 91 No 9 mo,  dead
    2 37 M +/+ 27,353 1148 96 No 9 mo,  dead
    3 62 M –/– 14 22   0 Yes 22 mo,  dead
    4 68 F +/+ 707,946 109,648 85 No 4 mo,  dead
    5 82 F +/+ 2884 1288 55 No 14 mo,  dead
    6 45 F –/+ 2399 0 100 Yes 9 mo,  dead
    7 30 F –/+ 130 167   0 Yes 6 mo,  dead
    8 49 F –/– 3311 0 100 Yes 12 mo,  dead
    9 79 M –/– 49 0 100 Yes 28 mo,  dead
  10 69 M –/– 9 0 100 Yes 5 mo,  dead
  11 74 M –/– 1000 800 20 Yes 5 mo,  dead
  12 69 F –/– 43 3 93 Yes 14 mo,  alive
  13 58 F –/+ 25,119 1995 92 Yes 8 mo,  alive
 CY, cytological free cancerous cells; F, female; M, male; mo, months; P, peritoneal metastasis. 
† Percentage of the reduced number of cancerous cells after intraperitoneal chemotherapy was calculated as follows: 
(a – b)/a × 100%; a, number of cancerous cells before intraperitoneal chemotherapy; b, number of cancerous cells af-
ter intraperitoneal chemotherapy. 
§ dead, died of disease: alive, alive with disease.
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Fig. 6.  Our treatment protocol for patients with scir-
rhous gastric cancer from 2002. 
be detected in peritoneal wash samples by real-
time RT-PCR from 4 patients after chemotherapy. 
We grouped the 8 patients into the “intraperitoneal 
chemotherapy effective group”.  In the remaining 
5 patients, the percentages of reduced numbers of 
cancerous cells after chemotherapy were less than 
90% (Table 1).  We named these patients as the 
“intraperitoneal chemotherapy ineffective group”. 
In these patients, cancer cells may have resistance 
to cisplatin chemotherapy.  The 50% survival 
period of the intraperitoneal chemotherapy effec-
tive group was longer (9 months) than that of the 
intraperitoneal chemotherapy ineffective group (6 
months), but the difference was not signiﬁcant (P 
= 0.342, Fig. 5) with a log rank test based on the 
Kaplan-Meier method.  
Fig. 5.  Survival periods of 13 scirrhous gastric cancer 
patients treated with our new treatment protocol.
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Our treatment protocol for patients with 
scirrhous gastric cancer
 
Our treatment protocol for patients with scir-
rhous gastric cancer is summarized in Fig. 6.  In 
the present study, the observation period was too 
short to estimate survival benefits of cisplatin-
based intraperitoneal chemotherapy for patients 
with scirrhous gastric cancer.  Therefore, continu-
ous follow-up is required. 
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